Sotera Health Shares Fall After JPMorgan Downgrade

Sotera Health's shares declined after JPMorgan downgraded the company to 'Underweight' from 'Neutral' and set a price target of $17. The stock is currently trading at $17.76, down 2.44% on the day and 1.15% over the past year.

Original reporting
Published Oct 14, 2026, 7:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 7:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$SHC
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

High
01

Why it matters

The downgrade is the primary new information, likely driving immediate share price decline.

02

Market read

Analyst downgrade with a lower target is a material catalyst for short‑term trading decisions.

03

What to watch

Potential upcoming contract wins or earnings beat could offset the downgrade impact.

Relevance 7/10Novelty 7/10Timing: today

Background

Sotera Health provides healthcare services and was recently covered by JPMorgan with a downgrade and new price target.

Market effects

Healthcare services sector may see modest weakness as a downgrade signals broader concerns.

U.S. market impact limited to Sotera Health and peers.

Minimal global effect beyond U.S. healthcare equities.

Counterpoint

If the downgrade reflects short‑term sentiment, the stock could be oversold and present a buying opportunity.

Key entities

  • JPMorgan

    Downgraded Sotera Health to Underweight and set a $17 price target.

Related articles

MedAI 8/10

Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

$SHCHighAI 8/10

Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMed

What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.